Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSabien Tech. Regulatory News (SNT)

Share Price Information for Sabien Tech. (SNT)

Share Price is delayed by 15 minutes
Get Live Data
3.25    0.00 (0.00%)
Bid:
3.00
Ask:
3.50
Spread: 0.50 (16.667%)
Market Cap: £1.03m
SNT Live PriceLast checked at - London Stock Exchange

Intraday Sabien Tech. Share Chart

Year End Trading Update

Today 07:00

RNS Number : 0169M
Sabien Technology Group PLC
13 July 2026
 

The information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the UK Market Abuse Regulation.

13 July 2026

Sabien Technology Group plc

("Sabien", the "Company" or the "Group")

Year End Trading Update

 

Sabien (AIM: SNT), a provider of energy efficiency technologies through its M2G intelligent boiler optimisation platform, provides a trading update ahead of the publication of its audited results for the year ended 30 June 2026 ("FY2026").

During FY2026 the Company focused on transforming Sabien into a higher-margin technology business centred on its M2G Cloud Connect platform, whilst strengthening its balance sheet and evaluating strategic opportunities to accelerate long-term shareholder value.

Trading

The M2G platform enables operators of commercial gas boilers to reduce energy consumption and carbon emissions by between 10% and 30%, typically delivering customers with a payback period of less than twelve months.

Customer orders received during FY2026 totalled over £908,000 (FY2025: £948,053), demonstrating resilient customer demand despite a challenging capital expenditure environment.

Revenue recognised during FY2026 is expected to be over £746,000 (FY2025: £846,015), subject to completion of the audit process.

Revenue recognised during the second half of the financial year principally reflected the timing of customer installation programmes, with a number of orders received in the period carried forward into FY2027 revenue.

The Company enters FY2027 with confirmed customer orders of over £196,000, compared with £59,453 at the beginning of FY2026, providing materially improved revenue visibility entering the new financial year.

Balance Sheet

During the year the Company completed several initiatives to strengthen its balance sheet, including the repayment of one of the loans previously provided by Parris Group Limited, as announced on 2 June 2026.

The Board believes these actions have materially improved the Company's financial position and provide a stronger platform from which to execute its commercial strategy.

Strategic Review

As announced on 21 May 2026, the Board commenced a review of strategic initiatives intended to accelerate long-term shareholder value.

The review has included discussions regarding potential strategic investment and commercial partnership opportunities intended to accelerate deployment of the M2G platform and support the Company's long-term growth strategy.

Those discussions remain ongoing. No agreement has been reached and there can be no certainty that any transaction will ultimately proceed.

The Board is evaluating alternative structures and will only pursue a transaction where it believes the commercial terms appropriately reflect the long-term strategic value of the Company, maintain an appropriate balance of commercial risk and reward, and are demonstrably in the best interests of all shareholders.

The strategic review has reinforced the Board's confidence in the long-term value of the Company's technology and in its ability to create shareholder value through continued independent execution, commercial partnerships or broader strategic relationships.

Accordingly, the Board's priorities remain focused on:

· expanding commercial routes to market;

· completing the migration of the M2G platform to the EVO architecture;

· improving operational leverage and cash generation; and

· maintaining disciplined capital allocation to maximise long-term shareholder value.

COF / b.grn

The Board continues to review the Company's investment in b.grn Group Limited and associated commercial arrangements relating to City Oil Field ("COF").

Whilst the Company's principal strategic focus remains the growth of its M2G business, the Board believes it is appropriate to preserve strategic flexibility in relation to its COF-related interests whilst its review continues.

Accordingly, the Board believes it is in shareholders' best interests to complete its review only once it has sufficient clarity to determine the long-term structure that best maximises shareholder value.

Richard Parris, Executive Chairman, commented:

"The past year has been one of disciplined execution. We have strengthened the Company's balance sheet, maintained resilient customer demand and entered FY2027 with a significantly stronger opening order book.

Over recent months the Board has carefully evaluated various strategic alternatives capable of accelerating shareholder value. Our responsibility is to ensure that any strategic transaction appropriately reflects the long-term strategic value of the Company, maintains an appropriate balance of commercial risk and reward, and delivers a superior outcome for shareholders compared with continued disciplined execution of our strategy.

Our priorities remain unchanged. We will continue to broaden our commercial routes to market, complete the migration of the M2G platform to the EVO architecture, improve operational efficiency and maintain disciplined capital allocation as we build a stronger and more scalable business.

Sabien today is a stronger business than it was twelve months ago. We have a stronger balance sheet, greater visibility entering the new financial year and a clearer strategic focus. That disciplined approach also extends to preserving strategic flexibility where the Board believes doing so has the potential to maximise long-term shareholder value."

For further information

Sabien Technology Group plc

Richard Parris, Executive Chairman

+44 (0)20 7993 3700

investors@sabien.com

Allenby Capital Limited (Nominated Adviser)

John Depasquale / Nick Harriss / Vivek Bhardwaj

+44 (0)20 3328 5656

AlbR Capital Limited (Broker)

Duncan Vasey / Lucy Williams

+44 (0)20 7469 0930

About Sabien Technology Group plc

Sabien Technology Group plc develops technologies that help organisations reduce energy consumption, lower carbon emissions and improve building efficiency through intelligent energy optimisation technologies.

The Company holds the London Stock Exchange's Green Economy Mark, recognising listed companies deriving more than 50% of revenues from products and services supporting the global green economy.

Website: www.sabien.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTRTMFTMTABBAF
Date   Source Headline
19th Mar 20218:45 amRNSHolding(s) in Company
11th Mar 20214:57 pmRNSHolding(s) in Company
10th Mar 20217:00 amRNSCorporate Update - US Subsidiary Established
8th Mar 202110:59 amRNSCorporate Update - Contract win
5th Mar 202112:32 pmRNSNotice of Annual General Meeting
5th Mar 20217:00 amRNSAppointment of Chief Financial Officer
3rd Mar 20214:33 pmRNSHolding(s) in Company
3rd Mar 202110:00 amRNSHolding(s) in Company
1st Mar 20215:06 pmRNSHolding(s) in Company
1st Mar 20217:00 amRNSHolding(s) in Company
26th Feb 20215:00 pmRNSTotal Voting Rights
26th Feb 202110:47 amRNSSignificant investment in emerging technology
24th Feb 20212:10 pmRNSHolding(s) in Company
24th Feb 202112:16 pmRNSHolding(s) in Company
23rd Feb 20213:45 pmRNSChange of Registered Office
22nd Feb 202110:35 amRNSResult of General Meeting and Total Voting Rights
12th Feb 20217:00 amRNSHolding(s) in Company
11th Feb 202111:03 amRNSHolding(s) in Company
10th Feb 202111:38 amRNSHolding(s) in Company
3rd Feb 20214:11 pmRNSPlacing and Notice of General Meeting
1st Feb 20217:00 amRNSAppointment of Non-Executive Director
28th Jan 20214:32 pmRNSHolding(s) in Company
28th Jan 20218:14 amRNSHolding(s) in Company
27th Jan 20211:28 pmRNSChange of Substantial Shareholding
27th Jan 20211:26 pmRNSHolding(s) in Company
25th Jan 20217:00 amRNSBoard Changes
20th Jan 20217:30 amRNSRestoration - Sabien Technology Group PLC
20th Jan 20217:00 amRNSWithdrawal from acquisition and other matters
12th Jan 20215:38 pmRNSFrequently asked questions regarding the GM
5th Jan 20217:00 amRNSPosting of Circular and Notice of General Meeting
21st Dec 20205:23 pmRNSHolding(s) in Company
21st Dec 20205:20 pmRNSHolding(s) in Company
2nd Dec 20205:14 pmRNSPosting of Annual Report and Accounts
19th Nov 20207:00 amRNSFinal Results & Update on Proposed Acquisition
5th Nov 20207:00 amRNSChange of Registered Office
2nd Nov 20207:00 amRNSUpdate on Acquisition
14th Sep 20203:30 pmRNSCorporate Update - Contract win
27th Jul 20207:00 amRNSChange of Adviser
27th Jul 20207:00 amRNSUpdate re. Suspension
6th Jul 20207:00 amRNSTrading Update
29th May 202011:15 amRNSManagement Change, Furlough Update
31st Mar 20207:00 amRNSSabien furloughs staff in response to C19 lockdown
20th Mar 20207:00 amRNSHalf-year Report
18th Mar 20207:00 amRNSChange of Adviser
20th Jan 20207:30 amRNSSuspension - Sabien Technology Group plc
20th Jan 20207:30 amRNSStatement re Press Comment
10th Jan 20202:00 pmRNSPrice Monitoring Extension
10th Jan 20201:30 pmRNSIssue of Equity
10th Jan 202010:15 amRNSHolding(s) in Company
8th Jan 20201:15 pmRNSResult of Meeting

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.